Monoclonal Gammopathy of Undetermined Significance

Monoclonal Gammopathy of Undetermined Significance — Trials · CancerIndex

Clinical trials

Registered studies

59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06140524	A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1)	recruiting	Phase 2	116	Regeneron PharmaceuticalsINDUSTRY	7	Jul 8, 2026	clinicaltrials
NCT06083922	A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)	recruiting	Phase 2	20	Memorial Sloan Kettering Cancer Center